Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endosome-associated trafficking regulator 1 (ENTR1)
- Target
- ENTR1
- Molecular classification
- Other (Trafficking regulator/Endosome-associated protein)
01
Overview
Endosome-associated trafficking regulator 1 (ENTR1) is a protein involved in regulating endosomal sorting and membrane trafficking, specifically mediating endosome-to-plasma membrane transport and recycling of cargo such as SNX27-retromer-dependent proteins (e.g., GLUT1)[2][3][7][8]. It also supports ciliogenesis, regulates cytokinesis, and controls cell surface presentation of key receptors, including the TNF receptor. ENTR1 is overexpressed in glioblastoma, where it promotes proliferation, invasion, and chemoresistance by modulating TNF signaling. It interacts with proteins such as PTPN13, GIT1, and elements of the retromer complex, affecting protein sorting, apoptosis regulation, and cell migration. ENTR1 is also identified as a colon cancer antigen (NY-CO-3, SDCCAG3) and is encoded by the ENTR1 gene on human chromosome 11[3][6][7].
- Other names
- SDCCAG3NY-CO-3Serologically defined colon cancer antigen 3Antigen NY-CO-3SDDAG3
02
Mechanism of action
Not established for any direct drugs; modulation of endocytic recycling and TNF signaling as a downstream mechanism of its cellular effects[1][2][3].
03
Biological functions
Membrane receptor sortingEndosome-to-plasma membrane traffickingEndocytic recyclingCiliogenesisCytokinesisPositive regulation of protein localization to ciliumRegulation of tumor necrosis factor (TNF) receptor presentationRegulation of apoptosis via TNF signaling pathwayCell proliferationCell invasion
04
Disease associations
Cancer (especially glioblastoma, colon cancer)Potential role in Parkinson’s disease (late-onset)Other (general involvement in cell survival and tumor progression)
05
Safety considerations
Not documented; as a trafficking regulator, broad inhibition may disrupt diverse essential cell functions but no specific clinical safety concerns are currently established.
06
Interacting drugs
None specifically identified in current datasets for direct interaction; temozolomide sensitivity is influenced by ENTR1 expression in glioblastoma cells[1].
07
Biomarkers
Overexpression in glioblastoma correlates with malignant grade and poor prognosis, making ENTR1 a potential prognostic biomarker for glioma[1].Potentially a marker for certain colon cancers (NY-CO-3, serologically defined colon cancer antigen 3)[3][6].
Beyond the preview
Go deeper on Endosome-associated trafficking regulator 1 (ENTR1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endosome-associated trafficking regulator 1 (ENTR1).